Effects of trazodone on viability in healthy and malignant ovarian cells

Abstract

OBJECTIVE: Trazodone is a triazole pyridine derivative antidepressant, the design of which dates back to the 1980s. It is mainly used in the treatment of major depression, as well as in psychological disorders such as anxiety, insomnia, and schizophrenia. Considering how widespread the use of antidepressants is, it sensible to evaluate the effects of this group of drugs in different pathologies other than the disease group they target. Cancer is the most common cause of death in the world after cardiovascular diseases. The use of trazodone in cancer patients and the relationship between the use of trazodone and the development of cancer have been reported in various studies. However, these studies are mostly observational and population-based and the molecular effects of trazodone in the cancer model are not clearly known. MATERIALS AND METHODS: Trazodone was applied to healthy ovarian cells and OVCAR-3 and A2780 ovarian cancer cell lines at a certain dose range (0.1-20 μM). Viability in cells treated and untreated with trazodone was analyzed by MTT assay. RESULTS: The results revealed that trazodone treatment (0.1-20 μM) did not have a significant effect on healthy and cancerous ovarian cell viability. CONCLUSION: Trazadone (0.1-20 μM) does not significantly affect the viability of both healthy and cancer cells.

Keywords

• tradazone
• OVCAR-3
• A2780
• ovarian
• cancer
• viability

References

1. Jackson EA, Cardoni AA, Rawls WN Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). Drug Intelligence & Clinical Pharmacy. 1982; 16 (1):7-13. doi:10.1177/106002808201600102
2. Haria M, Fitton A, McTavish D Trazodone. Drugs & Aging. 1994; 4 (4):331-355. doi:10.2165/00002512-199404040-00006
3. Earl DC, Van Tyle KM New pharmacologic agents for insomnia and hypersomnia. Curr Opin Pulm Med. 2020; 26 (6):629-633. doi:10.1097/mcp.0000000000000722
4. Belinskaia DA, Belinskaia MA, Barygin OI, Vanchakova NP, Shestakova NN Psychotropic Drugs for the Management of Chronic Pain and Itch. Pharmaceuticals (Basel). 2019; 12 (2). doi:10.3390/ph12020099
5. Pope HG, Jr., Hudson JI Antidepressant medication in the treatment of bulimia nervosa. Psychopathology. 1987; 20 Suppl 1:123-129. doi:10.1159/000284531
6. Odagaki Y, Toyoshima R, Yamauchi T Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S] GTPγS binding. Journal of Psychopharmacology. 2005; 19(3):235-241
7. Marek GJ, McDougle CJ, Price LH, Seiden LS A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992; 109 (1-2):2-11. doi:10.1007/bf02245475
8. Maeda I, Inoue S, Uemura K, Tanimukai H, Hatano Y, Yokomichi N, Amano K, Tagami K, Yoshiuchi K, Ogawa A, Iwase S Low-Dose Trazodone for Delirium in Patients with Cancer Who Received Specialist Palliative Care: A Multicenter Prospective Study. J Palliat Med. 2021; 24 (6):914-918. doi:10.1089/jpm.2020.0610

9. Tanimukai H, Murai T, Okazaki N, Matsuda Y, Okamoto Y, Kabeshita Y, Ohno Y, Tsuneto S An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer. Am J Hosp Palliat Care. 2013; 30 (4):359-362. doi:10.1177/1049909112452334
10. Voican CS, Corruble E, Naveau S, Perlemuter G Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014; 171 (4):404-415. doi:10.1176/appi.ajp.2013.13050709
11. Chen VC-H, Lin C-F, Hsieh Y-H, Liang H-Y, Huang K-Y, Chiu W-C, Lee Y, McIntyre RS, Chan H-L Hepatocellular carcinoma and antidepressants: a nationwide population-based study. Oncotarget. 2016; 8 (18)
12. Chubak J, Bowles EJ, Yu O, Buist DS, Fujii M, Boudreau DM Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control. 2016; 27 (1):125-136. doi:10.1007/s10552-015-0689-y
13. Hsieh Y-H, Chiu W-C, Lin C-F, Chan H-L, Liang H-Y, Lee Y, McIntyre RS, Chen VC-H Antidepressants and Gastric Cancer: A Nationwide Population-Based Nested Case-Control Study. PLOS ONE. 2015; 10 (11):e0143668. doi:10.1371/journal.pone.0143668
14. Chan H-L, Hsieh Y-H, Lin C-F, Liang H-Y, Huang K-Y, Chiu W-C, Lee Y, McIntyre RS, Chen VC-H Invasive Cervical Cancer and Antidepressants: A Nationwide Population-Based Study. Medicine. 2015; 94 (42)
15. Chang TS, Lin VC Melanogenesis inhibitory activity of two generic drugs: cinnarizine and trazodone in mouse B16 melanoma cells. Int J Mol Sci. 2011; 12 (12):8787-8796. doi:10.3390/ijms12128787
16. González SV, Puig FM, Martí SS, Sánchez MV, Capellán Mdel M, Martos MA [Trazodone: a new selective approach to the treatment of hot flashes induced by androgen deprivation in prostate carcinoma?]. Actas Urol Esp. 2009; 33 (6):635-638. doi:10.1016/s0210-4806(09)74201-9
17. Razavi D, Kormoss N, Collard A, Farvacques C, Delvaux N Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study. J Int Med Res. 1999; 27 (6):264-272. doi:10.1177/030006059902700602
18. Ozkan T, Hekmatshoar Y, Karabay AZ, Koc A, Altinok Gunes B, Karadag Gurel A, Sunguroglu A Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells. Leuk Res. 2021; 102:106523. doi:10.1016/j.leukres.2021.106523
19. Daniele S, Zappelli E, Martini C Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes. J Neuroinflammation. 2015; 12:225. doi:10.1186/s12974-015-0446-x
20. Harvey RF, Pöyry TAA, Stoneley M, Willis AE Signaling from mTOR to eIF2α mediates cell migration in response to the chemotherapeutic doxorubicin. Sci Signal. 2019; 12 (612). doi:10.1126/scisignal.aaw6763